Inex Innovate
Singapore, Singapore· Est.
Asia’s first women‑focused molecular diagnostics firm delivering rapid, early‑detection tests for cancer and fetal health.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Asia’s first women‑focused molecular diagnostics firm delivering rapid, early‑detection tests for cancer and fetal health.
OncologyReproductive Health
Technology Platform
Molecular diagnostics platform combining real‑time PCR, bisulfite‑based DNA methylation analysis, and proprietary fetal cell isolation for rapid, minimally invasive detection of cancer and prenatal conditions.
Opportunities
Expansion into emerging Asian markets for women’s health diagnostics and scaling NIPT services present significant growth avenues.
Risk Factors
Regulatory hurdles, reimbursement uncertainty, and competition from larger diagnostics firms could impede market penetration.
Competitive Landscape
Key competitors include Roche, Abbott, Guardant Health, and Illumina; Inex differentiates through rapid, methylation‑based assays specifically tailored to women’s and fetal health.